INmune Bio Inc (INMB)
11.62
-0.22
(-1.86%)
USD |
NASDAQ |
May 01, 16:00
11.62
0.00 (0.00%)
After-Hours: 17:06
INmune Bio Debt to Equity Ratio: 0.2601 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.2601 |
| September 30, 2023 | 0.2767 |
| June 30, 2023 | 0.2926 |
| March 31, 2023 | 0.267 |
| December 31, 2022 | 0.2445 |
| September 30, 2022 | 0.2296 |
| June 30, 2022 | 0.2084 |
| Date | Value |
|---|---|
| March 31, 2022 | 0.1919 |
| December 31, 2021 | 0.1802 |
| September 30, 2021 | 0.1632 |
| June 30, 2021 | 0.3319 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2020
0.3319
Maximum
Jun 2021
0.2035
Average
0.2296
Median
Sep 2022
Debt to Equity Ratio Benchmarks
| Biomarin Pharmaceutical Inc | 0.2144 |
| Sarepta Therapeutics Inc | 1.441 |
| Dare Bioscience Inc | 0.00 |
| Zevra Therapeutics Inc | 0.6913 |
| Kodiak Sciences Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 57.00M |
| Total Liabilities (Quarterly) | 18.86M |
| Shareholders Equity (Quarterly) | 38.14M |
| Current Ratio | 2.163 |
| Net Debt Paydown Yield | 0.47% |